Reliance Pharma Fund Direct Growth-0.09%

5Groww
-11.73%
1 Year Return
Equity
Sectoral/Thematic
5.0 star
6M
1Y
3Y
5Y
All

Fund Details

Reliance Pharma Fund Direct Growth

RiskModerately High
Min SIP Amount₹100
Expense Ratio1.36%
NAV148.02 (08 Jul 2019)
Fund Started31 Dec 2012
Fund Size2,344 Cr

Returns

1Y
3Y*
5Y*
Since inception*
Reliance Pharma Fund Direct Growth
-11.7%
-0.1%
5.5%
11.5%
Category Average
NA
NA
NA
-
Rank within category
NA
NA
NA
-
*All returns are annualized.
SIP
Lumpsum
I want to invest per month5,000
    For how many years?
    1 Year
    3 Years
    5 Years
    Estimated Value
    as per Historical Returns
    30
    with -11.7% annual returns

    Comparison

    Data not available
    Pros
    1. Age is more than 10 years
    2. Risk is lower compared to the benchmark
    3. Lower expense ratio
    4. 1Y Returns are higher than the benchmark
    5. 3Y Returns are higher than the benchmark
    6. 5Y Returns are higher than the benchmark
    7. 10Y Returns are higher than the benchmark
    Cons
    1. Risk-adjusted returns are lower compared to the category

    Top Holdings

    NameSectorInstrument% Assets
    Divi's Laboratories Ltd.HealthcareEquity10.5%
    Sun Pharmaceutical Inds. Ltd.HealthcareEquity10.1%
    Dr. Reddy's Laboratories Ltd.HealthcareEquity9.3%
    Aurobindo Pharma Ltd.HealthcareEquity8.2%
    Sanofi India Ltd.HealthcareEquity6.7%
    Syngene International Ltd.HealthcareEquity6.5%
    Cipla Ltd.HealthcareEquity5.8%
    Biocon Ltd.HealthcareEquity5.6%
    Abbott India Ltd.HealthcareEquity5.6%
    Lupin Ltd.HealthcareEquity5.0%
    See All

    Fund Managers

    addSailesh Raj Bhan
    Education
    Mr. Bhan is an MBA (Finance) and CFA.
    Experience
    Mr. Sailesh Raj Bhan has about 19 years experience in equity research and fund management, with over 10 years at Reliance Nippon Life Asset Management Limited (formerly Reliance Capital Asset Management Limited). He manages diversified equity schemes like Reliance Equity Opportunities Fund (the largest Flexicap Scheme in India with assets of USD 800 million) since its inception in 2005 and Reliance Top200 Fund (a large cap diversified equity fund) since its inception in 2007. In addition, for over 9 years, he has been managing two specialized sector funds - Reliance Pharma Sector Fund (the largest pharma sector fund in India) and Reliance Media and Entertainment Fund.
    Funds Managed

    Other Details

    Reliance Pharma Fund Direct Growth is a Equity Mutual Fund Scheme launched by Reliance Mutual Fund. This scheme was introduced to investors on 31 Dec 2012. Sailesh Raj Bhan is the Current Fund Manager of Reliance Pharma Fund Direct Growth.The fund currently has an Asset Under Management(AUM) of ₹2,344 Cr and the Latest NAV as of 08 Jul 2019 is ₹148.02.

    The Reliance Pharma Fund Direct Growth is rated Moderately High risk. Minimum SIP Investment is 100. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed within 1 year.

    Investment Objective

    To generate consistent returns by investing in equity or fixed income securities of pharma and other associated companies.

    Tax Implications

    Scheme Information Document(SID)

    ₹5000
    Min for First Investment
    ₹1000
    Min for Second Investment
    Exit load of 1% if redeemed within 1 year
    Exit Load

    Compare Funds

    Reliance Pharma Fund Direct Growth
    VS
    search

    About Reliance Mutual Fund

    Address
    Corporate Office : Reliance Centre, 7th Floor South Wing, OFf Western Express Highway, Santacruz(E) Mumbai-400055
    Phone
    022-33031000/30301111
    Launch Date
    29 Jun 1995
    Reliance Mutual Fund
    Asset Management Company
    Custodian
    ABN AMRO Bank
    Registrar & Transfer Agent
    Karvy
    Address
    NA
    Invest Now
    Enter investment amount
    + ₹1,000
    + ₹5,000
    + ₹10,000
    ONE TIME
    MONTHLY SIP
    Similar Funds
    Data not available